Emilio Bajetta1, Luigi Celio1, Nicoletta Zilembo1, Aldo Bono2, Domenico Galluzzo2, Maria Giulia Zampino1, Alessandra Longhi1, Leonardo Ferrari1, Roberto Buzzoni1
1Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
2Division of Surgical and Diagnostic Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
Tóm tắt
Aims and background Goserelin is a gonadotrophin-releasing hormone (GnRH) analogue that induces the suppression of gonadal steroidogenesis, and it could therefore be a medical alternative to irreversible surgical castration. We report the clinical and endocrine results from 40 goserelin-treated premenopausal patients with advanced breast cancer. Methods A depot formulation of the drug (3.6 mg s.c.) was administered fortnightly for the first 4 doses, and monthly thereafter. Gonadotrophins and estradiol (E2) levels were measured before and at specific times during the treatment. Results Objective responses were observed in 17 of the 38 evaluable patients (45%), six of whom achieved complete remission. The best responses were observed on soft tissues (65%). Castration E2 levels were achieved in all of the patients. Conclusions Our results confirm that goserelin is as effective as surgical oophorectomy in premenopausal advanced breast cancer.
